Advances in diagnosis and treatment of malignant pleural mesothelioma

Oncology Reviews

Giovanni Selvaggi¹  Giorgio Vittorio Scagliotti² 

[1] University of TurinDepartment of Clinicaland Biological SciencesThoracic Oncology UNIT,San Luigi HospitalOrbassano (Torino);University of Turin,Department of Clinical& Biological Sciences,Thoracic Oncology Unit,San Luigi Hospital,Regione Gonzole, 10,I-10043 Orbassano (TO);

关键词: Malignant Pleural Mesothelioma - Prognostic Factors - Mesothelin - Osteopontin - Chemotherapy - Pemetrexed - Targeted Therapy - Vascular Endothelial Growth Factor - Epidermal Growth Factor;   

DOI  :  

来源: DOAJ

【 摘 要 】

Malignant pleural mesothelioma (MPM) is an aggressive but relatively rare malignancy with median survival ranging from 8 to 14 months depending on stage and presentation of disease. New diagnostic procedures are urgently needed, selecting patients in earlier stages to evaluate therapeutic approaches which combine chemotherapy, surgery and radiotherapy. Combination chemotherapy represents the only resource available for advanced disease.The combination of cisplatin and pemetrexed is the treatment of choice. This review summarizes the latest developments in diagnostic techniques and the available therapeutic options for the management of MPM. Particular attention is given to the molecular basis of biologically targeted therapies to be used in the future.

【 授权许可】

Unknown